Even though a study conducted last year announced that there might be connection between cholesterol-lowering drugs and cancer, a closer look on the issue concluded that such an association is completely unfounded.

"The bottom line is that there is no evidence from this work, the largest study published to date, that the cholesterol-lowering ability of statins increases the risk of cancer," explained Dr. Richard H. Karas, director of preventive cardiology at Tufts Medical Center and leader of the group that reported the finding in the Journal of the American College of Cardiology.

These statin drugs include Zocor, Pravachol, Crestor and Lipitor and last year’s announcement was made by the same Dr. Richard Karas, who at the time gathered his information from 13 trials on the side effects reported by people taking the above mentioned medication.

This year’s research demanded 15 controlled trials with the detailed information from about 100,000 patients and the conclusion was that the drugs "lack an effect on cancer risk across all levels of on-treatment LDL cholesterol."

Dr. Richard Karas stated that this study is meant to reassure the patients taking these drugs, as they need to feel confident that their prescribed medication will help them get better and not worry about the possibility of their contribution to cancer.

Still, there is another study released last month, known as SEAS, on patients using Vytorin, claiming that they are significantly more likely to develop cancer than other patients who are given a placebo.

With all the uncertainty and questions raised by these reports, researchers will continue to investigate the issue, as at this point, none of them are considered 100 percent reliable.